A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 104
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : TRLs
Long Form : triglyceride-rich lipoproteins
No. Year Title Co-occurring Abbreviation
2020 Dietary Fatty Acids in Postprandial Triglyceride-Rich Lipoproteins Modulate Human Monocyte-Derived Dendritic Cell Maturation and Activation. DCs, moDCs, MUFAs, PUFAs, SFA
2020 Effects of Virgin Olive Oil and Phenol-Enriched Virgin Olive Oils on Lipoprotein Atherogenicity. CVD, HDL, LDL, VOO
2020 Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models. apo, CVD, LPL
2020 miRNA/Target Gene Profile of Endothelial Cells Treated with Human Triglyceride-Rich Lipoproteins Obtained after a High-Fat Meal with Extra-Virgin Olive Oil or Sunflower Oil. EVOO, SO
2020 Postprandial triglyceride-rich lipoproteins promote M1/M2 microglia polarization in a fatty-acid-dependent manner. FAs, MUFAs, SFAs
2020 Separation of postprandial lipoproteins: improved purification of chylomicrons using an ApoB100 immunoaffinity method. ---
2020 The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. apo, CVD, LDL
2019 Apolipoprotein CIII and diabetes. Is there a link? ApoCIII, LPL, VLDL
2019 GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients. LPL
10  2019 Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. APOC3, ASOs, CVD, T1DM
11  2019 Large triglyceride-rich lipoproteins in hypertriglyceridemia are associated with the severity of acute pancreatitis in experimental mice. ApoC3-tg, FFAs, PACs, VLDL
12  2019 Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease. apos, ASCVD, CAD, CAP, CI, OR, PAD
13  2019 PNPLA2 influences secretion of triglyceride-rich lipoproteins by human hepatoma cells. PNPLAs
14  2019 Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants. NDST-1, SDC1
15  2019 Vitamin E absorption and kinetics in healthy women, as modulated by food and by fat, studied using 2 deuterium-labeled alpha-tocopherols in a 3-phase crossover design. alpha-T, DLM
16  2018 Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism. ANGPTL8, apoC-III, CAD, LPL
17  2018 Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. CEC, HDL-C, HDLs
18  2018 Impaired thermogenesis and sharp increases in plasma triglyceride levels in GPIHBP1-deficient mice during cold exposure. BAT, GPIHBP1
19  2018 Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice. ApoCIII, ER, HTG
20  2018 NanoSIMS Analysis of Intravascular Lipolysis and Lipid Movement across Capillaries and into Cardiomyocytes. ---
21  2018 NanoSIMS imaging reveals unexpected heterogeneity in nutrient uptake by brown adipocytes. BAT, NanoSIMS, PVAT
22  2018 Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. HDL-C, LDL-C, SPPARMalpha, TG, TG
23  2018 Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. GLP-1, GLP-2, GLP-2R
24  2018 Transport of Apolipoprotein B-Containing Lipoproteins through Endothelial Cells Is Associated with Apolipoprotein E-Carrying HDL-Like Particle Formation. apoB-LPs, HD, HDL, IDLs, LD, LDLs, MAECs
25  2017 A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. CAD, FH, GRSs, GWAS, NGS
26  2017 A randomized trial and novel SPR technique identifies altered lipoprotein-LDL receptor binding as a mechanism underlying elevated LDL-cholesterol in APOE4s. LDLR, SFA, SPR
27  2017 Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. GPIHBP1
28  2017 Hepatic and Aortic Arch Expression and Serum Levels of Syndecan-1 in ApoE-/- Mice. HSPG, SDC1, TG
29  2017 Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. lbLDL, sdLDL
30  2017 Postprandial triglyceride-rich lipoproteins promote lipid accumulation and apolipoprotein B-48 receptor transcriptional activity in human circulating and murine bone marrow neutrophils in a fatty acid-dependent manner. ApoB48R, BM, MUFAs, PUFAs, SFAs, TGs
31  2017 The effects of exogenous fatty acids and niacin on human monocyte-macrophage plasticity. LCPUFAs, MUFAs, SFAs
32  2016 Acute effects of dietary fatty acids on osteclastogenesis via RANKL/RANK/OPG system. MUFA, TRAP
33  2016 Brief Communication: Discordant ability of the triglyceride to apolipoprotein B ratio to predict triglyceride-rich lipoprotein particle size in normal-weight and obese men. apoB, DLS, TG
34  2016 Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism. ---
35  2016 GPIHBP1 and Plasma Triglyceride Metabolism. LPL
36  2016 Intravenous Glucose Acutely Stimulates Intestinal Lipoprotein Secretion in Healthy Humans. ---
37  2016 Postprandial dietary fatty acids exert divergent inflammatory responses in retinal-pigmented epithelium cells. AMD
38  2016 Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. ApoB-48, GH, GHRH, GLP-1, STZ, T1D
39  2016 Targeting ApoC-III to Reduce Coronary Disease Risk. apoC-III, CAD, TGs
40  2016 Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease? CVD
41  2015 Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. 4-HNE, ApoCIII, ApoCIIItg, PCNA, ROS, SMCs, WT
42  2015 New insights into the pathophysiology of dyslipidemia in type 2 diabetes. CVD, HDL, LDL
43  2015 The pathophysiology of intestinal lipoprotein production. LPL, VLDLs
44  2014 Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size. apo, LDL-C, PAGE, RLP-C, TG, VLDL
45  2014 High-resolution imaging of dietary lipids in cells and tissues by NanoSIMS analysis. BSE, NanoSIMS
46  2014 Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance. apo, IR, IS
47  2014 Minor components of olive oil facilitate the triglyceride clearance from postprandial lipoproteins in a polarity-dependent manner in healthy men. OLIVE, POMACE, TG
48  2014 MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: effects of treatment with atorvastatin. FCH, MTP, TG
49  2014 Postprandial hypertriglyceridemia as a coronary risk factor. CVD, LDL
50  2014 Postprandial triglyceride-rich lipoproteins promote invasion of human coronary artery smooth muscle cells in a fatty-acid manner through PI3k-Rac1-JNK signaling. HCASMC, SFAs
51  2014 Recent advances in pharmacotherapy for hypertriglyceridemia. ANGPTLs, apo, ASOs, CETP, CVD, LPL, mAbs, MTTP, PCSK9, PPAR, PUFAs, SPPARMs, TG
52  2014 The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. HSPGs, LPL
53  2013 Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients. apoB, CETP, HDL, hs-CRP, LCAT
54  2013 Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? apo, CETP, FCR
55  2013 Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects. HSPG
56  2013 Highly purified eicosapentaenoic acid may increase low-density lipoprotein particle size by improving triglyceride metabolism in patients with hypertriglyceridemia. AA, EPA, LDL
57  2013 Novel role of enteral monosaccharides in intestinal lipoprotein production in healthy humans. apo
58  2013 Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. ---
59  2012 Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. SAL
60  2012 High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. apo, HCV, HCV, LVPs
61  2012 Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. ASOs, HSPGs, NT, PBS, SULF2, T2DM, TG, VLDL
62  2012 Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. apoB
63  2011 A high-fat meal promotes lipid-load and apolipoprotein B-48 receptor transcriptional activity in circulating monocytes. apoB-48, apoB48R
64  2011 Brown adipose tissue activity controls triglyceride clearance. BAT, LPL
65  2011 Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. HDL-C, LDL-C
66  2010 Acute resistance exercise attenuates fasting and postprandial triglyceridemia in women by reducing triglyceride concentrations in triglyceride-rich lipoproteins. TG
67  2010 DGAT1 participates in the effect of HNF4A on hepatic secretion of triglyceride-rich lipoproteins. HNF4A, siRNA
68  2010 Relationships between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients. apoA-I, ELISA, HDL, HTG, TG
69  2009 Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. ---
70  2008 An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? apoC-III, CHD, VLDL
71  2008 Leukocyte activation by triglyceride-rich lipoproteins. NTRL and ATRL
72  2008 Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. apo
73  2008 Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment. AD, MCI
74  2008 The ApoC-I content of VLDL particles is associated with plaque size in persons with carotid atherosclerosis. apoC-I
75  2007 Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. apoB-48, IDL, PRs
76  2007 Ghrelin interacts with human plasma lipoproteins. HDLs, LDLs, VHDLs
77  2006 A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. ---
78  2006 Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. APOE, HDLs
79  2006 Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism. hapoA-II, TG
80  2006 Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients with coronary artery disease. apo, CAD, LDL, oxLDL, QCA, RLPs, Sf
81  2006 Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. MTP
82  2005 Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. apo, VLDL
83  2005 Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers. apoB100, IDL, LDL, LPL, VLDL1
84  2005 Remnant lipoproteins and atherogenesis. EGF, FAK, HB-EGF, HDL, LDL, RLPs, SMC, TG
85  2005 The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. apo, CHD, IMT, VLDL
86  2004 Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. apo, HDL, LPL
87  2003 Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. apoC-III, CHD, HDL-C, LDL-C, non-HDL, OR
88  2003 Diabetic dyslipidaemia: from basic research to clinical practice. ---
89  2003 Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. apoB-100, AUC
90  2003 PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor. ApoB-48R, PPARs
91  2003 The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions. AD
92  2002 Association between serum apolipoprotein C(II) concentration and coronary heart disease. apo, CHD, OR
93  2002 Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. CE, CMs, HDL, VLDL
94  2002 Dyslipidemia of the metabolic syndrome. HDL, LDL, PPAR
95  2002 Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. apo, HDL, LDL, Sf, VLDL
96  2000 Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. apo, CAD, Sf, VLDLs
97  2000 Current treatment of insulin resistance in type 2 diabetes mellitus. HDL
98  2000 Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans. apo, IDL, LDL, VLDL
99  1999 Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. apo, AUC, IMT
100  1999 Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. apo, FCR, PR, PS